Physician profile
Sandra S Hoffmann
NPI 1477565893
$22,732.52
in general payments reported to CMS, 2019-2025
38 companies · $1,761 in 2025
The $1,761 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,842 · 2020: $3,925 · 2021: $3,785 · 2022: $4,327 · 2023: $2,691 · 2024: $1,402 · 2025: $1,761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,813 · Education: $40.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,813.25 |
| Education | $40.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,382.39 | 2019-2025 | |
| Pfizer INC. | $3,061.56 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $2,916.99 | 2020-2025 | Acthar |
| Amgen INC. | $2,278.48 | 2019-2025 | Enbrel, Uplizna, Otezla |
| Novartis Pharmaceuticals Corporation | $1,660.21 | 2019-2025 | |
| Janssen Biotech, INC. | $1,472.64 | 2019-2025 | Tremfya |
| Glaxosmithkline, LLC. | $1,050.88 | 2019-2025 | Benlysta, Nucala |
| Ucb, INC. | $903.42 | 2019-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $666.69 | 2019-2024 | Orencia |
| Lilly USA, LLC | $663.11 | 2019-2025 | Taltz, Mounjaro, Trulicity |
| Mallinckrodt Enterprises LLC | $616.67 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $421.39 | 2022-2025 | Saphnelo |
| Celgene Corporation | $386.67 | 2019 | |
| Ani Pharmaceuticals, INC. | $320.63 | 2022-2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.92 | 2019-2023 | Ofev |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Hoffmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.